Teva (NYSE: TEVA) EVP Mark Sabag awarded 141,478 restricted share units

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Ltd. executive Mark Sabag reported an equity award of 141,478 restricted share units effective January 27, 2026. Each unit represents a contingent right to receive one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share.

The restricted share units were received upon satisfaction of performance criteria tied to performance share units and remain subject to time-based vesting. These units are scheduled to vest on March 3, 2026. Following this award, Sabag directly beneficially owned 141,478 derivative securities linked to Teva ordinary shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sabag Mark

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See "Remarks"

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	01/27/2026		A		141,478		(2)	(2)	Ordinary Shares(3)	141,478	$0	141,478	D

Explanation of Responses:

1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

2. Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026.

3. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Remarks:

Executive Vice President, International Markets Commercial

	/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TEVA executive Mark Sabag report on January 27, 2026?

Mark Sabag reported receiving 141,478 restricted share units on January 27, 2026. These units are contingent rights to Teva ordinary shares or their cash value and were earned after performance criteria for performance share units were satisfied.

How many restricted share units did TEVA grant to Mark Sabag in this Form 4 filing?

Teva granted Mark Sabag 141,478 restricted share units in this transaction. Each unit can settle into one ordinary share or its cash value, subject to committee discretion and time-based vesting requirements outlined in the award terms.

When do Mark Sabag’s TEVA restricted share units vest according to the filing?

The restricted share units granted to Mark Sabag are scheduled to vest on March 3, 2026. They were issued after performance goals tied to performance share units were met and must satisfy time-based vesting before settlement into ordinary shares or cash.

What does each TEVA restricted share unit reported by Mark Sabag represent?

Each restricted share unit represents a contingent right to receive one Teva ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. Settlement occurs after the vesting conditions are fully satisfied.

How many TEVA derivative securities does Mark Sabag beneficially own after this transaction?

After the reported transaction, Mark Sabag beneficially owns 141,478 derivative securities. These are restricted share units linked to Teva ordinary shares, held directly, and subject to the vesting schedule and settlement terms described in the Form 4 footnotes.

Can the TEVA restricted share units granted to Mark Sabag be settled in cash instead of shares?

Yes. Each restricted share unit can be settled in one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. The final form of settlement depends on committee choice at the time of settlement.